|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Opioid-binding protein/cell adhesion molecule-like (OPCML) is a tumor-suppressor gene that is frequently inactivated in ovarian cancer and many other cancers by somatic methylation.
|
28775148 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Opioid binding protein/cell adhesion molecule-like gene (OPCML), a recently identified tumor-suppressor, is frequently inactivated by allele loss and CpG island promoter methylation in epithelial ovarian cancer.
|
16384911 |
2006 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
OPCML promoter methylation was significantly associated with an older age of the patients (p=0.022), an advanced pathological stage of ovarian cancer (p=0.023), and poor overall survival of ovarian cancer patients (p<0.001).
|
24327526 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
OPCML is frequently somatically inactivated in EOC by allele loss and by CpG island methylation.
|
12819783 |
2003 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel mechanism of OPCML-mediated tumor suppression and provide a proof-of-concept for recombinant OPCML protein therapy in epithelial ovarian cancers.
|
22585860 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
The methylation of OPCML was significantly altered in early-stage EOC compared with healthy donors (P<0.0001), and this supported the hypothesis that specific fcDNA methylation was able to distinguish patients with early-stage EOC from healthy donors.
|
28693156 |
2017 |
|
Carcinogenesis
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
Our results suggest that clinically occurring somatic missense mutations in OPCML have the potential to contribute to tumorigenesis in a variety of cancers.
|
31316070 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our data showed that OPCML gene promoter methylation may play an important role in the carcinogenesis of cervical carcinoma and OPCML gene may be a cervical carcinoma-associated candidate TSG (tumor suppressor gene).
|
18584347 |
2008 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
OPCML belongs to the IgLON family of Ig domain-containing GPI-anchored cell adhesion molecules and was recently found to be involved in carcinogenesis, while its role in gastric cancer remains unclear.
|
28407749 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The high frequency of OPCML promoter methylation in urothelial carcinomas suggests an important role for this epigenetic alteration in bladder carcinogenesis, highlighting its potential as an epigenetic biomarker for bladder urothelial carcinoma with prognostic significance.
|
21273058 |
2011 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
LMD in combination with cDNA microarray provides a unique support foe the identification of early expression profiles of differential genes and the expression pattern of 3 genes (OPCML, RNASE1 and YES1) associated with the progression of gastric cancer.
|
17109515 |
2006 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
OPCML plays an important role in gastric cancer, and may be a new prognostic indicator of gastric cancer.
|
27358143 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer.
|
28407749 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry results showed that the expression of OPCML in gastric cancer was 68.6% and the expression of OPCML was negatively correlated with the depth of tumor invasion and tumor differentiation degree (P < 005); OPCML expression, depth of tumor invasion, lymph node metastasis and distant metastasis were important factors affecting the prognosis of the survival of the patients (P <0.05).
|
27358143 |
2016 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we investigated OPCML expression in nonneoplastic brain tissue and 35 brain tumours (18 glioblastoma multiformes, five anaplastic gliomas, five meningiomas, six metastases and one medulloblastoma) and four glioma cell lines using quantitative reverse transcriptase polymerase chain reaction (RT-PCR).
|
17239010 |
2007 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Down-regulated OPCML expression might serve as an independent predictor for unfavorable prognosis of patients, and the biological behavior supports its role as a tumor suppressor in gastric cancer.
|
28407749 |
2017 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression of OPCML was detected by immunohistochemistry in 118 cases of gastric carcinoma.
|
27358143 |
2016 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
LMD in combination with cDNA microarray provides a unique support foe the identification of early expression profiles of differential genes and the expression pattern of 3 genes (OPCML, RNASE1 and YES1) associated with the progression of gastric cancer.
|
17109515 |
2006 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Previous studies have reported that the expression of the opioid binding protein/cell adhesion molecule-like (OPCML) gene was frequently downregulated in various of types of cancer.
|
29805691 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
OPCML expression was markedly reduced in tumor tissues and cancer cell lines.
|
28407749 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The high frequency of OPCML promoter methylation in urothelial carcinomas suggests an important role for this epigenetic alteration in bladder carcinogenesis, highlighting its potential as an epigenetic biomarker for bladder urothelial carcinoma with prognostic significance.
|
21273058 |
2011 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
|
18714356 |
2008 |
|
Congenital contractural arachnodactyly
|
0.020 |
Biomarker
|
disease |
BEFREE |
The combined marker between OPCML and HOXD9 showed sensitivity, specificity, PPV, and NPV of 62.50%, 100%, 100%, and 72.72%, respectively, which may be helpful to prevent a misdiagnosis between CCA and other biliary diseases.
|
30832707 |
2019 |
|
Congenital contractural arachnodactyly
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Low-protein expression was found in >70% of CCA with methylation of OPCML or DcR1.
|
21448164 |
2011 |